Details of the Drug Combinations

General Information of This Drug (ID: DMY0UEQ)

• Drug Name: VATALANIB (DMY0UEQ)
• Synonyms: Vatalanib; 212141-54-3; Vatalanib base; N-(4-chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine; PTK787; Pynasunate; CGP 79787; Vatalanib free base; PTK-787; Vatalanib (free base); Vatalinib; ZK-232934; CGP-79787; ZK222584; PTK/ZK; CHEMBL101253; N-(4-Chlorophenyl)-4-(4-pyridinylmethyl)-1-phthalazinamine; UNII-5DX9U76296; CHEBI:90620; YCOYDOIWSSHVCK-UHFFFAOYSA-N; 1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine; 5DX9U76296; NCGC00181350-01; 1-Phthalazinamine,N-(4-chlorophenyl)-4-(4-pyridinylmethyl)-; DSSTox_CID_26919

Indication

Solid tumour/cancer; ICD 11: 2A00-2F9Z; Status: Phase 2 [1]

• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

4 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Docetaxel + VATALANIB	DCL9UFM	Docetaxel	Ovarian Cancer	[2]
Everolimus + VATALANIB	DC0PRK5	Everolimus	Gastrinoma	[3]
Gemcitabine + VATALANIB	DC3M780	Gemcitabine	Pancreatic Cancer	[4]
Pemetrexed + VATALANIB	DC2RAD4	Pemetrexed	Unspecified Adult Solid Tumor, Protocol Specific	[5]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5705).
• [2] ClinicalTrials.gov (NCT00268918) Docetaxel and PTK787 in Metastatic Breast Cancer Patients and Gynecological Cancer Patients
• [3] ClinicalTrials.gov (NCT00655655) Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors
• [4] ClinicalTrials.gov (NCT00185588) Phase 1-2 Vatalanib and Gemcitabine in Advanced Pancreatic Cancer
• [5] ClinicalTrials.gov (NCT00390000) Vatalanib and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors